The hidden critical path
Investors naturally track design freeze, civil completion, equipment delivery and commissioning. Yet first production or patient admission depends on a different chain: licence-holder eligibility, product classification, quality-system maturity, evidence generation, authority review and closure of observations. These activities are connected. A late change to the product portfolio can alter room classification, validation protocols, labelling, clinical evidence and submission timing.
The programme schedule should show authority interactions and document maturity alongside construction progress. A “building complete” milestone is not an operational-readiness milestone.
Start with the regulatory endpoint
The first decision is not which certificate looks desirable; it is which legal endpoint permits the intended activity in the target market. An IVD manufacturing facility may require establishment licensing, ISO 13485 readiness, product technical documentation and local registration. A hospital or laboratory follows a different licensing chain involving clinical scope, professional staffing, radiation, pharmacy, biosafety or waste approvals.
Infinity IVD maps the applicable endpoint, responsible legal entity, submission sequence and evidence owner before the basis of design is approved. Competent authorities retain all certification and authorisation decisions.
Control dependencies at every gate
Design inputs must be traceable to regulatory requirements. User requirements feed DQ; installed systems feed IQ; operating ranges feed OQ; and routine-process evidence feeds PQ. Supplier documents, calibration status, environmental monitoring, method verification and training records must arrive in the correct sequence. Missing upstream evidence creates expensive downstream repetition.
A live regulatory deliverables register should name every document, author, approver, prerequisite and target date. It is reviewed with the same discipline as the procurement schedule.
What investors should demand
A credible programme identifies the licence applicant, local authorised roles, product families, classification assumptions, QMS boundary, validation plan and authority-review allowance. It also includes schedule contingency for questions and corrective actions.
The feasibility gate should state what can be achieved, what remains authority-dependent, the evidence cost and the earliest defensible operational date—not simply the construction completion date.
Investor checklist
- Named licence holder and accountable regulatory lead
- Market-specific approval map with dependencies
- QMS implementation and audit-readiness dates
- Validation evidence linked to design and commissioning
- Authority-review allowance and response ownership
This briefing is a decision framework, not legal, regulatory or financial advice. Requirements vary by jurisdiction, product and facility scope. Certification and market authorisation remain subject to competent-authority decisions.
Commission a regulatory critical-path review
Translate the briefing into a project-specific scope, responsibility map and feasibility workplan.